We asked John Oyler, an American entrepreneur and the chairman, cofounder, and CEO of BeiGene, why he decided to build a global biopharmaceutical company with roots beginning in China. His answer may surprise you.
Like it or not, the U.S. and China are hugely important to one another. And while the U.S. is currently the world’s largest economy, that could soon change — and as early as next year.
A Life Science Leader reader shares their thoughts on why the biopharmaceutical industry’s reputation is so dismal, but also proposes solutions for how to repair it.
With the biopharmaceutical industry’s reputation at an all-time low, Life Science Leader’s Rob Wright looks to share little-known stories of the good being done by employees of biopharma. This first installment involves Antoine Yver, M.D., EVP and global head of R&D at Daiichi Sankyo, who helped to cofound a 501(c)3 nonprofit restaurant, The Blue Bears Special Meals.
Our Chief Editor shows how The Business Roundtable’s recent statement redefining the purpose of an American corporation can be related to our cover feature this month on Audentes Therapeutics.
Matt Patterson, chairman and CEO of Audentes Therapeutics, shares the experiences that prepared him for building the gene therapy company he cofounded into a publicly traded business valued at nearly $2 billion, in just seven years.
Catherine Clark, a professor and Duke University and impact investment expert, provides a comprehensive overview of impact investing, a growing trend sure to catch on in life sciences.
Thinker50 member and Columbia Business School Professor Rita Gunther McGrath, Ph.D., believes we have seen the end of sustainable competitive advantage, but has some solutions for businesses open to building strategies around transient competitive advantage.
Chief Editor Rob Wright discusses the implications of the recent Gallup poll indicating pharma presently being the most poorly regarded of all industries in the eyes of Americans.